Imaging Core

成像核心

• 批准号: 10620831
• 负责人: Richard E. Carson
• 金额: $ 34.71万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-06-15 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10620831
• 关键词: Alzheimer' s Disease; Alzheimer' s disease pathology; Alzheimer’s disease biomarker; Amyloid; Atlases; Autopsy; Behavior; Behavioral Model; Binding; Biological Markers; Brain; Clinical; Clinical Research; Clinical Trials; Cognitive; Data; Data Analyses; Data Set; Development; Dimensions; Disease Pathway; Disease Progression; Functional Magnetic Resonance Imaging; Functional disorder; Future; Goals; Hippocampus; Human; Image; Image Analysis; Imaging Device; Imaging technology; Individual; Infrastructure; Link; Magnetic Resonance; Magnetic Resonance Imaging; Measurable; Measures; Methodology; Methods; Modeling; Multimodal Imaging; NIH Program Announcements; Nerve Degeneration; Noise; Paper; Participant; Patients; Pattern; Phenotype; Positron-Emission Tomography; Principal Investigator; Radiation Dose Unit; Research; Research Personnel; Resolution; Resources; Scanning; Statistical Data Interpretation; Statistical Models; Structure; Study Subject; Synapses; System; Techniques; Tracer; Training; Work; aged; analytical method; connectome; connectome based predictive modeling; data management; deep learning; density; experience; fluorodeoxyglucose; glucose metabolism; human data; human imaging; human subject; imaging biomarker; imaging study; in vivo; in vivo imaging; innovation; mild cognitive impairment; multimodal data; multimodality; neuroimaging; neuropathology; next generation; nonhuman primate; novel; novel strategies; pre-clinical; programs; research study; success; tau Proteins

Project Summary: Yale ADRC Imaging Core The Yale Alzheimer Disease Research Center has the overall goal to advance understanding and treatment of Alzheimer’s disease (AD). This effort requires integration of a wide array of core functions, including Clinical, Neuropathology, and Neuroimaging. Human imaging studies allow for the development of imaging biomarkers of AD, characterization of the temporal sequence of AD pathology, and lead to better assignment of patients to clinical research studies and clinical trials. Imaging is a major strength at Yale, as exemplified by the breadth and depth offered by the Yale PET Center and the Yale Magnetic Resonance Research Center (MRRC). In the PET Center, an example of recent significant work is the introduction of PET synaptic imaging with the SV2A tracer 11C-UCB-J. In MRI, the Yale MRRC has generated numerous novel methods to characterize an individual’s functional connectome and relate the functional organization to behavior and clinical variables Overall, these two Centers develop cutting edge imaging technologies and apply these techniques to answer important clinical questions. By creating this Yale ADRC Imaging Core (YAIC), we leverage the vast experience of Yale’s imaging strengths to provide state-of-the-art acquisition and analysis of imaging data and to focus on the development of novel approaches to AD. The YAIC will provide a common infrastructure for acquisition, processing, and analysis of multimodal imaging data, to support and train AD investigators and develop the next generation of imaging tools. The current and future methods will be applied to ongoing imaging studies to acquire a rich, multi-faceted and multi-modality dataset in human subjects. In addition, the translational component of this program examines the utility of nonhuman primates (NHPs) as a model for human AD. The Imaging Core will perform the following specific aims: Aim 1: To develop and optimize PET image and data analysis strategies to facilitate within- and between-subject comparisons. Multi-tracer within- subject correlations are important, involving amyloid, tau, synaptic density, and glucose metabolism. Aim 2: To enhance our MR-based functional connectome modeling to better functionally phenotype patients and link brain to behavior. This approach provides a functional profile for each individual while localizing the networks and revealing the network organizing principles supporting these functions. Aim 3: To develop and enrich multi- modality analyses between PET and fMRI for within- and between-subject studies. The combination of fMRI- based connectivity with the regional patterns of neurodegeneration measurable with PET provides an ideal opportunity for understanding the pathways of disease progression. Aim 4: To extend the methodologies developed for human analysis to NHP data. Ongoing studies in aged NHPs are being performed, providing the opportunity to compare in vivo PET and MR imaging with post-mortem measures provided by the Neuropathology Core.

项目摘要：耶鲁 ADRC 成像核心 耶鲁大学阿尔茨海默病研究中心的总体目标是促进对阿尔茨海默病的理解和治疗 阿尔茨海默病 (AD) 需要整合广泛的核心功能，包括临床、 神经病理学和神经影像学研究允许开发成像生物标志物。 AD 的诊断、AD 病理学的时间序列特征，并导致更好地分配患者 临床研究和临床试验是耶鲁大学的主要优势，其广泛性就是例证。 耶鲁 PET 中心和耶鲁磁共振研究中心 (MRRC) 提供的深度和深度。 PET 中心，最近重要工作的一个例子是使用 SV2A 引入 PET 突触成像 示踪剂 11C-UCB-J 在 MRI 中，耶鲁 MRRC 已经开发出许多新颖的方法来表征 个体的功能连接组并将功能组织与行为和临床变量联系起来 总体而言，这两个中心开发了尖端成像技术，并应用这些技术来回答 通过创建耶鲁 ADRC 成像核心 (YAIC)，我们利用了广泛的知识。 耶鲁大学成像优势的经验提供最先进的成像数据采集和分析， YAIC 将为 AD 提供一个通用的基础设施。 多模态成像数据的采集、处理和分析，以支持和培训 AD 研究人员和 开发下一代成像工具将应用于当前和未来的方法。 成像研究以获得丰富的、多方面的、多模态的人类受试者数据集。 该计划的翻译部分检查了非人类灵长类动物（NHP）作为模型的效用 人类 AD 成像核心将实现以下具体目标： 目标 1：开发和优化 PET 图像和数据分析策略，以促进受试者内和受试者间的多示踪剂比较。 主题相关性很重要，涉及淀粉样蛋白、tau、突触密度和葡萄糖代谢。 增强我们基于 MR 的功能连接组模型，以更好地对患者进行功能表型分析并建立联系 这种方法在定位网络的同时为每个人提供了功能概况。 并揭示支持这些功能的网络组织原则：发展和丰富多元网络。 PET 和 fMRI 之间的模态分析用于受试者内和受试者间研究 fMRI 的组合。 与可通过 PET 测量的神经变性区域模式的基于连通性提供了理想的 目标 4：扩展方法学。 正在对老年 NHP 数据进行人体分析而开发，提供了 有机会将体内 PET 和 MR 成像与尸检结果进行比较 神经病理学核心。